Shots:

• The P-l study involves assessing CVnCoV in patients with COVID-19. The interim data showed that CVnCoV (2-12µg) was well tolerated and induced strong binding and neutralizing Ab responses to the first indication of T cell activation
• The immune response was found to be comparable to recovered COVID-19 patients- closely mimicking the immune response after natural COVID-19 infection. The manuscript is available on medRxiv and will be submitted for publication in a peer-reviewed journal
• The P-l clinical study began in June 2020 in Germany and Belgium in collaboration with the CEPI. CureVac plans to initiate a pivotal P-IIb/III clinical study by the end of 2020

­ Ref: CureVac | Image: CNN